Challenger joins rush to biotechnology

capital gains tax high net worth colonial first state capital gains director

3 July 2000
| By Stuart Engel |

Challenger International is looking to join Colonial First State in the hot managed investments market of biotechnology with the intention to raise up to $40 million through the soon-to-be listed BioTech Capital.

Challenger International is looking to join Colonial First State in the hot managed investments market of biotechnology with the intention to raise up to $40 million through the soon-to-be listed BioTech Capital.

BioTech Capital will invest in Australian biotechnology focusing an areas such as genomics, proteomics, medical devices bioinformatics and enabling technologies.

"To date this type of investment has generally only been available to high net worth and institu-tional investors," says BioTech Capital director Harry Karelis.

"While there are other biotech pooled funds, with BioTech Capital, investors can now participate in these investments at the very low entry level of $2,000 in a totally liquid investment."

Challenger says investors will also enjoy the tax advantages that pooled development funds at-tract, with no capital gains tax on share price appreciation, wile Australian investors would re-ceive tax-free dividends or full-franked dividends.

"The aim of BioTech Capital is to maximise wealth creation through investment in entities which exhibit the potential for exceptional performance and value growth with an achievable exit strat-egy for the benefit of all shareholders in the company."

The investments of BioTech will be handled by Challenger subsidiary Challenger BioTech Man-agement. Challenger will draw on advice by Foursight Associates whose principals include Sir Gustav Nossal, Professor David Pennington and Graham Mitchell.

Read more about:

AUTHOR

Recommended for you

sub-bgsidebar subscription

Never miss the latest news and developments in wealth management industry

MARKET INSIGHTS

GG

So shareholders lose a dividend plus have seen the erosion of value. Qantas decides to clawback remuneration from Alan ...

3 weeks 6 days ago
Denise Baker

This is why I left my last position. There was no interest in giving the client quality time, it was all about bumping ...

3 weeks 6 days ago
gonski

So the Hayne Royal Commission has left us with this. What a sad day for the financial planning industry. Clearly most ...

4 weeks ago

The decision whether to proceed with a $100 million settlement for members of the buyer of last resort class action against AMP has been decided in the Federal Court....

1 week 5 days ago

A former Brisbane financial adviser has been found guilty of 28 counts of fraud where his clients lost $5.9 million....

3 weeks 5 days ago

The difference between a Record of Advice and Statement of Advice is the crux of the FSCP’s latest determination against a relevant provider. ...

4 weeks 1 day ago

TOP PERFORMING FUNDS